Insight Molecular Diagnostics Inc. (IMDX): restructuring charge — Oncocyte cuts ~20% of workforce; expects $0.3M severance charges in Q2 2023

Insight Molecular Diagnostics Inc.

Reduction in force involving approximately 20% of employees, announced April 12, 2023.
Estimated charges of about $0.3 million for severance and benefits in Q2 2023.
Management says cuts align with kitted product strategy and extend cash runway into 2024.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.95

Insight Molecular Diagnostics Inc. announced a restructuring with charges of approximately $0.3 million related to employee severance and benefits costs affecting workforce (approximately 20% of its workforce).

Type: restructuring
Charge: approximately $0.3 million related to employee severance and benefits costs
Affected area: workforce
Headcount: approximately 20% of its workforce

Exact text from the filing

On April 12, 2023, Oncocyte Corporation (the “Company” or “Oncocyte”) , announced a reduction in force involving approximately 20% of its workforce (the “Reduction”), which management believes will extend Oncocyte’s cash runway in 2024. In connection with the Reduction, Oncocyte estimates that it will incur charges of approximately $0.3 million related to employee severance and benefits costs in the second quarter of 2023.

View on SEC.gov

Browse all restructurings & charges →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-012154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.